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Background. Live attenuated influenza vaccines (LAIVs) stimulate a multifaceted immune response including cellular immu-
nity, which may provide protection against newly emerging strains. This study shows proof of concept that LAIVs boost preexisting, 
cross-reactive T cells in children to genetically diverse influenza A virus (IAV) strains to which the children had not been exposed.
Methods. We studied the long-term cross-reactive T-cell response in 14 trivalent LAIV–vaccinated children using the fluo-
rescent immunospot assay (FluoroSpot) with heterologous H1N1 and H3N2 IAVs and CD8+ peptides from the internal proteins 
(matrix protein 1 [M1], nucleoprotein [NP], polymerase basic protein 1 [PB1]). Serum antibody responses were determined by 
means of hemagglutination inhibition assay. Blood samples were collected before vaccination and up to 1 year after vaccination.
Results. Preexisting cross-reactive T cells to genetically diverse IAV strains were found in the majority of the children, which 
were further boosted in 50% of them after receipt of LAIV. Further analyses of these T cells showed significant increases in CD8+ T 
cells, mainly dominated by NP-specific responses. After vaccination with LAIV, the youngest children showed the highest increase 
in T-cell responses.
Conclusion. LAIV boosts durable, cross-reactive T-cell responses in children and may have a clinically protective effect at the 
population level. LAIV may be a first step toward the desired universal influenza vaccine.
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T cells play a key role in immunological responses in the con-
trol and clearance of viral infections. Both CD4+ and CD8+ T 
cells have been associated with less severe influenza in humans 
[1, 2]. Influenza remains among the most important respira-
tory viruses, and the World Health Organization estimates 
that 20%–30% of children and 5%–10% of adults are infected 
during an annual epidemic [3]. Vaccination is the most cost- 
effective strategy to combat the public health burden of influ-
enza; however, current influenza vaccines require annual updat-
ing to cover new emerging strains, which constantly evolve to 
circumvent antibodies. In the absence of neutralizing antibod-
ies, current inactivated influenza vaccines have poor efficacy 
against newly emerging influenza A  viruses (IAVs), as was 
evident during the 2009 pandemic. In 2013–2014, substantial 
drift in the H3N2 virus caused a mismatch between circulating 
and vaccine strains, leading to excess mortality [4]. Thus, the 
challenge is to develop broadly cross-reactive vaccines that are 
protective in the face of constant viral evolution [5].
CD8+ T cells, an important T-cell subtype, are capable of kill-
ing virus infected cells by cytotoxic activity. Early work showed 
that cytotoxic CD8+ T cells play an important role in the recov-
ery from influenza infection, in the absence of protective anti-
bodies [6]. More recently, protection against disease and viral 
shedding was shown with cross-reactive CD4+ and CD8+ T cells 
specific to conserved internal viral proteins [2, 7].
Current inactivated influenza vaccines induce strain-specific 
antibodies and not CD8+ T cells [8]. However, live attenuated 
influenza vaccine (LAIV) mimics natural infection with viral 
replication in the upper respiratory tract and induces multi-
faceted immune responses, including antibodies and CD4+ 
and CD8+ T cells [8, 9]. Although LAIV elicits durable strain- 
specific T cells, whether cross-reactive CD8+ T cells are induced 
is less clear [8–10]. Studies have shown induction of CD8+ T 
cells after LAIV vaccination, but the kinetics and durability of 
these T cells was not reported [8, 11]. 
Partial protection through T cells may also have a clinical 
impact, reducing the severity of influenza-associated illness. 
Such evidence was found in a recent murine study, wherein 
M A J O R  A R T I C L E
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of 
America. This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted 
reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1093/infdis/jix165
Received 1 February 2017; editorial decision 23 March 2017; accepted 26 March 2017; published 
online March 27, 2017.
Presented in part: First International Meeting on Respiratory Pathogens, Singapore, 
September 2015.
Correspondence: K. G. I. Mohn, MD, PhD, Influenza Centre, Laboratory Building 5th floor, 
Haukeland University Hospital, 5021 Bergen, Norway (Kristin.mohn@uib.no).
Downloaded from https://academic.oup.com/jid/article-abstract/215/10/1527/3091449
by Universitetsbiblioteket i Bergen user
on 05 March 2018
1528 • JID 2017:215 (15 May) • Mohn et al
LAIV was found to induce CD8+ T cells, which provided 
protection from heterosubtypic challenge [12]. Thus, a key 
question is whether LAIV is capable of inducing protection- 
associated cross-reactive T cells in humans. Furthermore, it is 
critical to know whether LAIV generates broadly protective T 
cells against novel strains to which individuals have no previous 
exposure. To address this question, we conducted a pediatric 
clinical trial in Norway, to test for influenza-specific cross- 
reactive T cells and determine their specificity and durability 
after immunization with trivalent LAIV.
MATERIAL AND METHODS
Study Subjects and Vaccine
Fourteen healthy children (median age, 4  years old; range, 
3–15 years) were recruited in 2013–14 (October-February) and 
immunized with 1 (n = 4; ≥10 years old) or 2 doses (n = 10; <10 years 
old; 28-day interval) of trivalent LAIV (Fluenz) containing A/
California/07/09(H1N1), A/Victoria-like/361/11(H3N2)/A/
Texas/50/12(/H3N2) and B/Wisconsin/1/2010 strains. The study 
was a follow-up study, with a design identical to that of the pre-
vious season [9]. Healthy children and adolescents (3–18 years 
old) scheduled for elective tonsillectomy at the Ear-Nose and 
Throat Department at Haukeland University Hospital in Bergen, 
Norway, were eligible for inclusion. The exclusion criteria were 
the manufacturers contraindications for vaccination. All parents 
and children >12  years old provided informed consent before 
inclusion, and ethical and regulatory approval was obtained 
(www.clinicaltrials.gov; NCT01866540). 
Sequential blood samples were collected before and after vac-
cination, for up to 1 year. Peripheral blood mononuclear cells 
(PBMCs) were isolated using Cell Preparation tubes (CPT) and 
cryopreserved at −150°C in 90% fetal calf serum/10% dimethyl 
sulfoxide until used. Plasma samples were aliquoted and frozen 
at −80°C.
Viruses and Peptides
Homologous, wild-type vaccine strains (A/California/07/09 
[H1N1] and A/Victoria-like/361/11[H3N2]/A/Texas/50/12/
[H3N2]) and heterologous, wild-type (A/Solomon Islands/ 
03/06[H1N1] and A/Switzerland/9715293/13[H3N2]) strains 
were used to measure immune responses. Owing to limited 
blood volume, we tested only 1 heterologous virus per subtype. 
Synthetic, influenza-specific major histocompatibility com-
plex class 1–restricted matrix protein 1 (M1), nucleoprotein 
(NP), and polymerase basic protein 1 (PB1) peptide pools were 
obtained from the BEI Resources, VA, USA.
Hemagglutination Inhibition Assay
Plasma samples were analyzed in duplicate (starting dilution, 
1:10) with 0.7% turkey red blood cells and 8 hemagglutinating 
units of the H1N1 and H3N2 homologous vaccine and heter-
ologous wild-type viruses (50 μL per well). Negative samples 
were assigned a hemagglutination inhibition (HI) titer of 5 for 
calculation purposes [13].
FluoroSpot Assay
Antigen-specific interferon (IFN) γ+, interleukin 2 (IL-2)+, 
and IFN-γ+/IL-2+ cytokine-secreting T cells were quantified at 
the single-cell level with the FluoroSpot assay (Mabtech) [14]. 
Briefly, PBMCs were thawed, and 400 000 PBMCs per well for 
CD8+-conserved peptide pools (2 μg/mL) or 300 000 PBMCs 
per well for live virus (multiplicity of infection, 5), anti-CD3 
T-cell activator (positive control), or lymphocyte medium alone 
(negative control) were incubated overnight at 37°C. Spot-
forming units (SFUs) were counted using an automated reader 
(Advanced Imaging Devices), and background values were 
subtracted.
RESULTS
In the current study, we examined the ability of LAIV to induce 
cross-reactive antibodies and T cells in children. To evaluate the 
immune responses to the heterologous H1N1 strain, we chose 
the historical Solomon Islands/06(H1N1) strain, which circu-
lated 7 years before our study, and before 10 (71%) of the chil-
dren were born. To evaluate the heterologous H3N2, we chose 
the Switzerland/13(H3N2) strain, which was antigenically 
distinct from the Victoria/12-like(H3N2)/Texas/12(H3N2) 
vaccine strain. This circulated in 2014–2015, the year after our 
study, so none of the children could have been exposed. There 
is a larger genetic distance between the H1N1 (0.22 in evolu-
tionary distance) than the H3N2 strains (0.025 in evolutionary 
distance; Figure 1).
Cross-Reactive Antibodies to Homologous and Heterologous  
Strains After LAIV
We first assessed the vaccine strain-specific antibody elic-
ited by LAIV. Before vaccination, HI antibodies above the 
protective threshold (HI titer, ≥40) were detected in ≥50% of 
children to the vaccine strains, in 7 and 8 of 14 children to 
California/09(H1N1) and Victoria/12-like(H3N2), respec-
tively (Figure 2). All children reached HI titers of >40 for the 
Victoria/12-like(H3N2) strain, with a trend of an increase 
(P = .09) after 1 dose. Protective titers were maintained in 92% 
of children (12 of 13) at 1 year to the Victoira/12-like(H3N2), 
whereas only 3 children sero converted to California/09(H1N1) 
after LAIV, with 69% (9 of 13) having protective titers at day 
56. When we studied the individual responses, all children with 
high prevaccination HI titers (≥40) maintained high titers (>80) 
up to 1 year after vaccination for both homologous vaccine 
strains, consistent with previous observations [9, 15].
Furthermore, we assessed HI antibodies to heterologous 
influenza strains. We detected before vaccination HI antibod-
ies against the drifted Switzerland/13(H3N2) in 7 of 14 (50%) 
of the children. We found very high titers in 2 of 14 (14%) of 
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Figure 1. Phylogenetic trees for the influenza A H1 and H3 strains. The phylogenic trees show the genetic divergence from the homologous vaccine viruses and the heterolo-
gous wild-type strains. The influenza A/H1N1 strains were the California/09(H1N1) vaccine strain and the heterologous historical Solomon Islands/06(H1N1) strain from 2006. 
The influenza A/H3N2 strains were the homologous Texas/12(H3N2) live attenuated influenza vaccine (LAIV) vaccine strain and the drifted wild-type Switzerland/13(H3N2) 
strain from 2014–2015, the year after the trial. Phylogenetic trees were built using the neighbor-joining method with Poisson correction in MEGA software, version 6.0.6 [16].
Figure 2. Hemagglutination inhibition (HI) responses to the homologous and heterologous influenza AHN1 and H3N2 strains. The HI responses after live attenuated influenza 
vaccine (LAIV) are shown for homologous vaccine strains, California/09(H1N1) (A, B) and Victoria/12-like(H3N2) (equivalent to Texas/12[H3N2]) (E, F) and the heterologous wild-
type influenza strains, Solomon06(H1N1) (C, D) and Switzerland/13(H3N2) (G, H). Bars represent geometric mean titers with 95% confidence intervals,* indicating a trend of an 
increase (P = .09). The HI responses are shown as individual responses; each symbol represents a single child, and a titer of 40, considered the protective level, is indicated by 
dotted lines. To compare HI responses over time, the nonparametric Kruskal-Wallis test was used, with correction for multiple comparisons; differences were considered signif-
icant at P < .05.
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the children (aged 11 and 13 years) against the more divergent 
Solomon Islands/06(H1N1) strain (Figure 2C and 2D). LAIV 
did not generally boost cross-reactive antibodies to either het-
erologous strain, but 3 of 14 children had a postvaccination 
increase in HI titers to the Switzerland/13(H3N2) (Figure 2G 
and 2H). There was no difference in HI titer fold change between 
the homologous and heterologous strains (Supplementary 
Figure 1).
Boosting of Influenza-Specific T-Cell Responses to Cross-Reactive Strains 
After LAIV
We examined the vaccine strain-specific and cross-reactive 
T-cell responses after LAIV in the FluoroSpot assay. A level 
of 100 SFUs/106 PBMCs has earlier been suggested to be pro-
tective after LAIV [17]. We observed prevaccination protec-
tive INF-γ+ T cells (>100 SFUs/106 PBMCs) in 10 and 8 of 14 
children in response to the vaccine California/09(H1N1) and 
Victoria/12-like(H3N2) strains, respectively. LAIV boosted the 
homologous T-cell response to the vaccine strains in 36%–50% 
of the children, 5 of 14 for California/09(H1N1) and 7 of 14 for 
the Victoria/12-like(H3N2) (data not shown).
To test whether LAIV induced cross-reactive T-cell 
responses, we measured influenza-specific responses to the 
wild-type historical Solomon Islands/06(H1N1) and the drifted 
Switzerland/13(H3N2) strains, which circulated the year 
after the study (Figure  3). High levels of preexisting IFN-γ+ 
T cells were also observed to the heterologous strains in most 
children, with 10 of 14 and 10 of 12 children with all time 
points available having levels >100 SFUs/106 PBMCs for the 
Solomon Islands/06(H1N1) and Switzerland/13(H3N2) strains, 
respectively.
Remarkably, although 11 of 14 children showed no increase 
in HI antibodies to the heterologous Switzerland/13(H3N2) 
strain, a significant increase in IL-2+– and IFN-γ+IL-2+–
secreting T cells was observed after LAIV. Importantly, these 
cross-reactive T cells were maintained for up to 6 months after 
vaccination. We found that the children either responded to or 
remained nonresponders to both the homologous Victoria/12-
like(H3N2)/Texas/12(H3N2) (n = 7) and the heterologous 
Switzerland/13(H3N2) strains (n = 6) (Figure 3). 
For the more antigenically diverse (H1N1) strain, we observed 
a trend of an increase in IFN-γ+ T cells after 1 dose (day 28) 
Figure 3. Durability of cross-reactive T-cell cytokine responses to heterologous influenza A virus strains after live attenuated influenza vaccine (LAIV). The long-term 
responses up to 1 y, for influenza-specific interferon (IFN) γ+, interleukin 2 (IL-2)+, and IFN-γ+IL-2+ T-cell responses after LAIV are indicated per 106 peripheral blood mononu-
clear cells (PBMCs). Each symbol represents an individual child, and bars represents group means with standard errors of the mean. For statistical analysis of the heterologous 
T-cell response after vaccination, the nonparametric Kruskal-Wallis test was used, with correction for multiple comparisons; differences were considered significant at P < 
.05. * ; ** . Abbreviation: SFUs, spot-forming units.
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(P = .08). However, when we examined the individual responses, 
5 of 12 (naive) children who had no prevaccination antibodies 
to Solomon Islands/06(H1N1) showed increases in IFN-γ+ T 
cells in response to this older virus after 1 dose (Supplementary 
Figure 3). Looking at both strains, there was no significant dif-
ference in T-cell fold change between the homologous vaccine 
and the heterovariant strains (Supplementary Figure 2), indicat-
ing a response toward conserved viral proteins. Furthermore, 
for the individual immune responses, we observed that the 
children achieved either protective antibody titers (3 of 14 chil-
dren), or high levels of T cells (71–957 SFUs/106 PBMCs; 11 of 
14 children) after LAIV [17]. 
LAIV-Induced Increase in Protection-Associated, Cross-reactive CD8+ T 
Cells
To investigate whether the observed T cells were the protection- 
associated, cross-protective CD8+ T cells, we used CD8+-specific 
peptide pools in the FluoroSpot assay (Figure 4A–4C). 
Overall, the influenza-specific IFN-γ+ CD8+ cells showed the 
highest frequencies, throughout the study. Only 4 of 14 chil-
dren had background levels of influenza-specific IFN-γ+ CD8+ 
T cells of >100 SFUs/106 PBMCs, whereas 11 of 14 had levels 
of >20 SFUs/106 PBMCs [7]. The IFN-γ+ responses increased 
significantly after 1 dose of LAIV (P < .01). For IFN-γ+ 11 of 
14 children showed increases after 1 dose, 8 of 14 had levels 
>100 SFUs/106 PBMCs, and 12 of 13 had an increase at day 
56 compared with before vaccination. For IL-2+ and IL-2+/
IFN-γ+ cells, there was a trend of an increase (P = .08), with an 
increase in 8 of 14 children (60%) at day 28. The IFN-γ+ cells 
were maintained up to 6 months, declining toward prevaccina-
tion levels within 1 year, whereas the long-term IL-2+ responses 
remained higher than prevaccination levels at days 180 and 360 
(Figure 4A and 4B). Seven children (50%) had increases in all 
cytokine combinations after the first dose. Interestingly, we 
Figure 4. Long-term and individual influenza-specific CD8+ T-cell responses after live attenuated influenza vaccine (LAIV) vaccination. Influenza-specific interferon (IFN) γ+, 
interleukin 2 (IL-2)+ and IFN-γ+IL-2+ CD8+T-cell responses up to 1 y after LAIV are indicated per 106 peripheral blood mononuclear cells (PBMCs). Bars represent means with 
standard errors of the mean. A–C, The IFN-γ+ (A), IL-2+ (B), and IFN-γ+IL-2+ (C) cytokine responses are shown for all children. D–I, The kinetics of the CD8+ T-cell response with 
individual responses are shown for children <10 y old (n = 10) (D–F) or ≥10 y old (n = 4) (G–I). For statistical analyses of the postvaccination response, the Wilcoxon matched-
paired signed rank test was used for the 12 subjects with available samples up to day 180. * ; ** . Abbreviation: SFUs, spot-forming units.
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found a significant correlation between fold increases in CD8+ 
T cells and cross-reactive T cells after 1 dose (P = .01 for H1N1 
and P = .01 for H3N2).
Impact of Age and Priming Status on CD8+ T-Cell Responses
Because age determines the number of vaccine doses admin-
istered, we stratified the children’s CD8+ T-cell responses 
accordingly (Figure 4D–4I). Children ≥10 years old showed 
significantly higher CD8+ IFN-γ+ levels after vaccination (n = 4) 
than younger children (n = 10) (P = .008) (Figure 5), with 
increases after 1 dose in 3 or 4 older children. However, children 
<10 years old (n = 10), showed a trend of a significant increase 
in IFN-γ+ cells (P = .06) at day 28, with the majority (8 of 10; 
80%) showing an increase after the first dose (Figure 4D–4F). 
Importantly, after the recommended second dose, all but 1 child 
<10 years old showed an increase from baseline. There was no 
overall correlation between age and fold change in CD8+ T cells 
after vaccination (data not shown). 
When we further studied the CD8+ T-cell response by the 
antibody priming status, of 10 children who were seroneg-
ative (HI  titer, <10) to either homologous vaccine strain 
before vaccination, 9 had increases in IFN-γ+, IL-2+, or IFN-
γ+IL-2+ CD8+ T cells after the first dose. We found no correla-
tion between HI titers and the fold increase in IFN-γ+CD8+ 
responses at any time point (data not shown) or between HI 
titers before vaccination and CD8+T-cell fold change at day 28 
(Supplementary Figure  3). Importantly, all serological nonre-
sponders to California/09(H1N1) (HI titer of 5 at days 0–56) 
showed increases in CD8+ T cells. Interestingly, there was an 
overall increase in CD8+ T-cell numbers for the H1N1 strain in 
both seropositive and nonresponding children (Supplementary 
Figure 4).
The T cell response to individual influenza proteins
To study the influence of each protein, the NP, PB1, and M1 
responses were measured separately (Figure 5). Because the IFN-
γ+ T cells dominated the response, we focused on this cytokine 
when studying the individual responses. We found the highest 
CD8+ responses to NP, with relatively low CD8+ levels to PB1 
and M1 (Figure 5A). However, both the M1- and NP-specific 
CD8+ cells increased after the first dose. The NP response was 
significantly boosted (P = .02) after the second dose, maintained 
up to 6 months, followed by a decline, although the response 
remained above prevaccination levels. The combination of 
anti-NP and anti-M1 IFN-γ+ responses increased significantly 
only by days 28 and 56 (P = .03). When we further dissected 
the NP response, the effect of age became apparent. The chil-
dren ≥10 years old showed significantly higher levels of anti-NP 
CD8+ T cells than those <10 years old (P = .008) (Figure 5B).
DISCUSSION
Natural infection provides the basis for cross-reactive T cells, 
and historical studies provide evidence for heterovariant pro-
tection after influenza infection [1, 6, 18]. Current research 
toward the desired universal influenza vaccine includes focus 
on T cells and their potential for cross-protection across dif-
ferent IAVs. As opposed to inactivated influenza vaccines, the 
LAIV mimics natural infection, inducing broad T-cell responses 
[8, 9]. We hypothesized that these T cells could cross-react to 
heterovariant influenza strains. Our study found that up to 70% 
of children had preexisting cross-reactive, influenza-specific T 
cells in response to heterosubtypic IAVs in the absence of preex-
isting antibodies (70% to H1N1, 60% to H3N2). Furthermore, 
we found that the LAIV boosted T-cell responses to genetically 
diverse, wild-type IAVs, to which the children could not have 
been previously exposed and to which LAIV did not generally 
induce antibody responses.
Cross-reactive T cells are considered important in limiting 
disease severity and death in the absence of strain-specific anti-
bodies, such as during a pandemic [2, 6]. It is noteworthy that 
the overall levels of preexisting heterovariant influenza-specific 
IFN-γ T cells were high, with most children having levels of 
>100 SFUs/106 PBMCs before vaccination, which were boosted 
Figure 5. Influenza-specific individual CD8+ peptide responses after live attenuated influenza vaccine (LAIV) vaccination. A, Influenza-specific response to individual pep-
tides covering the NP, M1, and PB1 proteins of influenza A virus, with means and standard errors of the mean. B, Because the dominant response was to the NP peptide, 
interferon (IFN) γ+ NP-specific CD8+ peptide responses are shown according to age ≥10 or <10 y. The total response (NP, M1, and PB1) is shown in A. To compare the response 
over time between the 2 age groups, the nonparametric Mann-Whitney test was used, with differences considered significant at P < .05. Abbreviations: M1, matrix protein 
1; NP, nucleoprotein; PB1, polymerase basic protein 1.
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after receipt of LAIV. These findings indicate a considerable 
number of preexisting influenza-specific T cells with cross- 
reactive potential in our pediatric population, confirming find-
ings at a population level (>20 SFUs/106 PBMCs) [7]. 
These preexisting T cells may explain the diversity of clini-
cal symptoms after infection, from asymptomatic to fulminant 
pneumonia [19]. Remarkably, in children without detectable 
HI antibodies to divergent strains, we found high levels of 
cross-reactive T cells in all but 2 children before vaccination. 
Importantly, our study found that LAIV boosted cross-reactive 
T-cell responses to historical and drifted wild-type IAVs not 
included in the vaccine. This important finding could imply a 
considerable protective effect at the population level if LAIV 
is administered to children. Indeed, signs of herd immunity, 
despite circulation of drifted influenza strains, as well as a 
reduction in child hospitalization rates, have been observed in 
the United Kingdom, where widespread LAIV vaccination of 
school children was conducted, [20, 21].
A previous study by Mohn et al [9], the longest reported 
follow-up of cellular responses in LAIV vaccinated chil-
dren, showed increased levels of T cells for up to 1 year. The 
results from the current study provide proof of concept that 
LAIV boosts cross-reactive and protection-associated CD8+ 
T cells. This important finding may help explain the clinical 
observation that LAIV provides protection from culture- 
confirmed illness in the absence of a boost in HI antibodies 
[22]. This is also supported by the correlation in CD4+ and 
CD8+ T-cell responses, but no correlation between the cellular 
and HI responses [8]. 
Similarly, we found no correlation between HI titer and 
CD8+ T-cell responses, and children with high HI titers showed 
no increase in CD8+ T-cells, while children with low HI titers 
showed and increase, indicating a response in the cellular or 
humoral immunecompartement, but not both (Supplementary 
Figures 3 and 4). One child (15 years old) responded in both 
the humoral and cellular compartments, and 1 (3 years old) did 
not respond in either compartment, highlighting the individual 
variation in human immune responses. However, because LAIV 
is dependent on viral replication to elicit immune responses, we 
cannot exclude the possibility that LAIV viruses are neutral-
ized by preexisting antibodies. In agreement with our pediat-
ric findings, a Russian LAIV study among young adults found 
cellular immune responses in all subjects without an increase 
in HI antibody titers [23]. In the Russian study, baseline CD4+ 
and CD8+ responses were predictive of post-LAIV cellular 
immune responses. Although the Russian LAIV is considered 
more immunogenic, it induced HI antibodies in ≤50% of the 
subjects, suggesting that the lack of HI response we found is 
more likely linked to the LAIV itself, rather than to the Russian 
or US/European LAIV.
Our study is the first to our knowledge to show long-term, 
cross-reactive CD8+ T-cell responses after LAIV vaccination, 
with the youngest children having the largest increases. 
Generally, the T-cell response after infection is thought to be 
rapid, and the peak was earlier than day 7 in adults during the 
2009 pandemic [24]. Although we found significant increases 
28 days after LAIV, larger increases may have been detected if 
we had sampled at an earlier time point.
Cross-reactive T-cell responses are directed primarily to 
conserved internal viral proteins (M1, NP, PB1) [1, 2]. CD8+ 
T cells have been found essential in limiting disease, and pro-
viding protection on heterosubtypic challenge in animal studies 
[12, 25]. Moreover, human studies have shown that preexisting 
CD8+ and CD4+ T cells, specific for these conserved proteins, 
have been associated with lower viral shedding and less severe 
influenza disease [1, 2, 7]. Interestingly, lower levels of CD8+ T 
cells were observed in adults hospitalized with pandemic influ-
enza disease, perhaps leaving them vulnerable to severe disease 
[26, 27]. Whether it is the magnitude or the functionality of the 
CD8+T-cell response that has a protective effect remains to be 
elucidated [28]. We found a significant increase in the CD8+ 
IFN-γ-response after LAIV, with the greatest response toward 
the NP protein, supporting the importance of including NP in 
broadly protective T-cell–inducing vaccines [7].
Our study is limited by its few subjects, and larger studies 
will therefore be needed to confirm our findings. Furthermore, 
we do not know the duration of the CD8+ T cells beyond 1 year, 
hence the need for repeated annual vaccination. However, if 
these CD8+ T cells provide protection from severe illness, LAIV 
could prove to be an important public health countermeasure 
in a situation with mismatch of epidemic and seasonal vac-
cine strains, or in the face of a novel pandemic virus, before a 
strain-specific vaccine is available. The finding that 50% of the 
children had increases in CD8+ T cells may be explained by the 
HLA genetic diversity, with the peptides perhaps not covering 
all HLA types.
It is debated whether LAIV is effective in older age groups. 
Children’s developing immune systems, combined with the 
impact of previous exposures to influenza, may influence the 
age-related response to LAIV. Our results show age-dependent 
differences in the response, supporting immunization of the 
youngest children with 2 doses, although most respond after the 
first dose. Importantly, our findings suggest that if a child has 
a CD8+ T-cell response, this will be cross-reactive. The single 
child that did not respond with CD8+ T cells after vaccination 
did not respond to either cross-reactive strain.
In contrast to cross-reactive T cells, only strain-specific anti-
bodies neutralize the virus. However, a study in LAIV vaccinated 
children found an induction of cross-reactive HI antibodies to a 
drifted H3N2 strain, and the children who were vaccinated but 
nevertheless infected showed milder symptoms than infected 
controls [29]. Interestingly, although LAIV protected against 
a closely related H3N2 strain, recent epidemiological studies 
showed no sterilizing immunity against more antigenically 
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divergent strains [19]. However, cross-reacting neutralizing 
antibodies have been found for closely related strains [30–32]. 
Overall, we did not find cross-reactive antibodies to the 
Solomon Islands/06(H1N1) strain, except in 2 older children, 
indicating earlier infection. However, 3 children responded to the 
drifted Switzerland/13(H3N2) strain, which has a closer genetic 
relationship to the Texas/12(H3N2) vaccine strain (Figure 1). 
The general lack of antibody response may also explain the fail-
ure of LAIV to provide sterilizing immunity in the 2013–2014 
season, when the Switzerland/13(H3N2) variant emerged. 
However, we found durable vaccine, strain-specific antibodies 1 
year after vaccination, with lower responses to the H1N1 than to 
the H3N2 strain, similar to findings during the 2012–2013 influ-
enza season [9, 13]. This strain variability could be a result of the 
current H1N1 strain being less immunogenic than during earlier 
seasons, an issue being addressed by the vaccine manufacturer 
[33, 34] Currently, there is disparity between LAIV effectiveness 
data in the United States and in Europe. In the United States, 
the lack of effectiveness caused concern and withdrawal of the 
prior LAIV recommendation. In Europe, LAIV has been found 
to provide protection and is recommended. The reason for these 
differences is currently unknown, and investigation is ongoing, 
but it could be related to the vaccine, the viruses, or the popula-
tion’s exposure history [20, 35].
Efficacy studies measure viral replication in the upper respira-
tory tract in patients with influenza like illness; cross-reactive T 
cells cannot provide sterilizing immunity but could limit severe 
disease. Perhaps an improvement in LAIV efficacy studies would 
be to divide vaccinated subjects who become infected into mild 
and severe infection groups, potentially illuminating a clinical 
protective effect. Indeed, a study in the United Kingdom found 
LAIV to reduce hospitalizations in children [20]. Norway does 
not have effectiveness data, but surveillance data for the study 
year indicated that approximately 60% and 30% of influenza 
infections were due to H1N1 and H3N2 strains, respectively [36].
In conclusion, our unique trial is the first to show long-term 
cross-reactive T cells elicited by LAIV in children. Importantly, 
our study found that these preexisting and protection- 
associated CD8+ T cells were detectable in young children in 
the absence of antibodies, which is proof of concept that the 
LAIV boosts CD8+ T-cell responses to conserved antigens. 
The responses were durable, indicating that a cellular immune 
response could possibly last through a whole influenza season. 
Although our findings were limited by small numbers, they 
support our hypothesis that the LAIV has the potential to pro-
vide cross-protective immunity to drifted and potentially het-
erovariant strains. Hence, it could possibly be a step toward the 
desired universal influenza vaccine.
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